226 related articles for article (PubMed ID: 21074200)
1. Editorial comment.
Singer EA; Srinivasan R; Bratslavsky G
J Urol; 2011 Jan; 185(1):66. PubMed ID: 21074200
[No Abstract] [Full Text] [Related]
2. Editorial comment.
Akhtar NH; Tagawa ST
J Urol; 2011 Jan; 185(1):59. PubMed ID: 21074812
[No Abstract] [Full Text] [Related]
3. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Choueiri TK; Xie W; Kollmannsberger C; North S; Knox JJ; Lampard JG; McDermott DF; Rini BI; Heng DY
J Urol; 2011 Jan; 185(1):60-6. PubMed ID: 21074201
[TBL] [Abstract][Full Text] [Related]
4. Editorial comment.
Pomara G; Francesca F
Urology; 2011 May; 77(5):1146; author reply 1146-7. PubMed ID: 21539964
[No Abstract] [Full Text] [Related]
5. Editorial comment.
Uzzo RG
J Urol; 2009 Nov; 182(5):2171. PubMed ID: 19758642
[No Abstract] [Full Text] [Related]
6. Editorial comment.
Klatte T
J Urol; 2009 Dec; 182(6):2606. PubMed ID: 19836796
[No Abstract] [Full Text] [Related]
7. Editorial comment.
Keeley FX; Minervini A
Urology; 2009 Sep; 74(3):640-1; author reply 642. PubMed ID: 19716920
[No Abstract] [Full Text] [Related]
8. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy.
You D; Jeong IG; Ahn JH; Lee DH; Lee JL; Hong JH; Ahn H; Kim CS
J Urol; 2011 Jan; 185(1):54-9. PubMed ID: 21074811
[TBL] [Abstract][Full Text] [Related]
9. Editorial comment on: Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery.
Eggener S
Eur Urol; 2010 Mar; 57(3):472. PubMed ID: 19359087
[No Abstract] [Full Text] [Related]
10. Editorial comment on: Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery.
Russo P
Eur Urol; 2010 Mar; 57(3):472-3. PubMed ID: 19359086
[No Abstract] [Full Text] [Related]
11. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment.
Campbell SC; Lane BR
J Urol; 2010 Feb; 183(2):485; discussion 485. PubMed ID: 20006871
[No Abstract] [Full Text] [Related]
13. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
Carver BS
J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
[No Abstract] [Full Text] [Related]
14. Editorial comment on: Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality.
Bex A
Eur Urol; 2007 Nov; 52(5):1436-7. PubMed ID: 17420089
[No Abstract] [Full Text] [Related]
15. Editorial comment.
Russo P
Urology; 2010 Feb; 75(2):275-6; author reply 276. PubMed ID: 20152477
[No Abstract] [Full Text] [Related]
16. Is tumor response important for renal carcinoma?
Inman BA; George DJ
Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245
[No Abstract] [Full Text] [Related]
17. Editorial comment.
Russo P
Urology; 2009 May; 73(5):1082. PubMed ID: 19394510
[No Abstract] [Full Text] [Related]
18. Editorial comment.
Maranchie JK
J Urol; 2010 Feb; 183(2):492. PubMed ID: 20006863
[No Abstract] [Full Text] [Related]
19. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
[No Abstract] [Full Text] [Related]
20. Metastatic renal cell carcinoma: recent advances in the targeted therapy era.
Di Lorenzo G; Autorino R; Sternberg CN
Eur Urol; 2009 Dec; 56(6):959-71. PubMed ID: 19748725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
